Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

By LabMedica International staff writers
Posted on 19 Oct 2026

Non-small cell lung cancer (NSCLC) represents the largest U. More...

S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein marker may not fully capture the complexity of the tumor-immune response. To provide a broader assessment, a newly validated RNA-based test integrates signals from the tumor-immune microenvironment to predict potential benefit from immunotherapy.

Cofactor Genomics (San Francisco, CA, USA) has announced published clinical validation of OncoPrism-NSCLC in npj Precision Oncology, a peer-reviewed Nature Portfolio journal. The test is based on the same multidimensional RNA biomarker used in OncoPrism-HNSCC, a clinically validated, Medicare-covered test for recurrent or metastatic head and neck squamous cell carcinoma. The OncoPrism platform uses patented Gene Expression Classifiers that combine machine learning with RNA analysis to generate high-dimensional models of tumor biology and treatment response.

The NSCLC validation was conducted through Cofactor’s multisite PREDAPT clinical trial. The study found that the underlying biomarker was represented across NSCLC, clear cell renal cell carcinoma, colon adenocarcinoma, triple-negative breast cancer, and bladder carcinoma. Investigators from 17 U.S. health care systems then calibrated the test specifically for NSCLC and validated its performance against treatment response and survival outcomes.

Patients with high OncoPrism scores were significantly more likely to respond to immune checkpoint inhibitors and had significantly longer survival, with median overall survival twice that of the remainder of the study population. The test appeared specifically predictive of immunotherapy response rather than generally prognostic, as it was not associated with outcomes among patients treated with chemotherapy or other therapies.

The publication also evaluated OncoPrism alongside PD-L1 testing and suggested that the two biomarkers may provide complementary information across PD-L1 expression levels. Among tumors with high PD-L1 expression, defined as a score of at least 50%, patients classified as OncoPrism-high had significantly longer progression-free and overall survival.

“Precision medicine is not just about finding a target. It is about prioritizing treatment selection based on a patient’s current condition and presence of actionable biomarkers. This work represents an emerging approach to immunotherapy diagnostics: integrating RNA signals from the tumor-immune microenvironment into a clinically validated prediction, rather than asking a single marker, like PD-L1 expression, to represent a complex biological response,” said Dr. Howard Bailey, Chief Medical Officer of Cofactor Genomics.

Related Links
Cofactor Genomics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.